A Phase 1 Study of DS-3201b in Subjects with Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
MD Anderson Study Status
This research study tests an investigational drug called DS-3201b. An investigational drug is a medication that is still being studied and has not yet been approved by the United States Food and Drug Administration (FDA). The FDA allows DS-3201b to be used only in research. It is not known if DS-3201b will work or not. This study consists of two parts. The first part (Part 1) is a dose escalation that will enroll subjects with AML or ALL that did not respond or no longer respond to previous standard therapy. The purpose of Part 1 of this research study is to determine the highest dose a patient can tolerate or recommended dose of DS-3201b that can be given to subjects with AML or ALL. Once the highest tolerable dose is determined, additional subjects will be enrolled at that dose into Part 2 of the study.
Information and next steps
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
For general questions about clinical trials: